Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Oct 23 - Oct 28
As of February 2026, retatrutide is not approved by the FDA or any major regulatory agency
Less inflammatory damage to the liver-SHBG circuit means more SHBG, which means more testosterone bound up and inactive, which means fewer visible androgenic symptoms
All payments are cash-pay with no insurance coordination In-person visits are not offered
Integrated Support Nutrition counseling, behavioral strategies, and exercise recommendations to reinforce your medication plan
Beyond that, a head-to-head comparison from the SURMOUNT-5 trial illustrates the difference clearly: Participants taking tirzepatide lost an average of 20.2% of their body weight compared to 13.7% with semaglutide
